Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: not everything is a BUY after a dramatic dip

January 31, 2018 7:39am

Sector intelligence and perspective

A rebound after a short interest release date …

Where momentum and volume moved in tandem

Followed by volatility (VIX) rising to its highest level in more than 5 months

Out and about: Casting a sector “pall” as Bellicum Pharmaceuticals (BLCM) takes a big hit on news of having received an FDA notice that U.S. studies of BPX-501 have been placed on a clinical hold. Gene therapy companies were oversold; however, I see “some” rebound!

When you get a sector that's facing more than its share of challenges; sentiment gets drained exposing the risk of development platforms, fundamentals and expectation as well as share pricing.

Pre-open indications: 4 SELLs and 1 BUY

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 45 min ago
RegMed Investors (RMi) Closing Bell: welcoming the upside trend

13 hours 45 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.